Easy, accessible & risk free

The first, scientifically proven, non-surgical treatment for AMD, Diabetic Retinopathy, and Cataract.

Cutting-edge technology

Innovative ocular drug delivery system. Simple to apply eye-drops. Pantented system.

Prevents progressive blinding

Safeguards vision offering an improved quality of life. Cost-effective.

Innovation

Romanian-American
collaboration

We have developed an inovative topical formulation with lutein (eye drops) which is non-invasive and easy to apply into the eyes.

Lutein was entrapped in a nanostructured carrier and placed in a thermosensitive, mucoadhesive gel. The novel formulation facilitated and improved the access of lutein to inner eye structures, leading to a superior ocular bioavailability, but also improved the chemical stability of the active substance.

X-eLUT is a  joint Romanian-American collaborative project led to the development of an innovative formula able to effectively fight against cataract and AMD. The first of its kind, patented formula, offers the chance of a simple, accessible, non-invasive and highly efficient local treatment.

Michael Holmes

Ceo, Ab Tact

How does it work?

Our innovative product (eye drops) delivers through the eye with high efficiency a natural antioxidant – lutein, normally occurring within the eye, and offers a boosted photooxidative protection of the ocular structures, particularly in this case the crystalline. Although there are plenty of orally administered lutein-based dietary supplements available on market, scientific studies demonstrated insufficient bioavailability and very poor clinical efficiency.

Age-related, degenerative eye diseases like cataract, macular degeneration or diabetic retinopathy are a leading cause of vision loss worldwide with a severe negative impact on patients’ quality of life.The increase of ageing population, genetic factors and the exposure to agressive environmental factors like blue light and UV light play an important role in the development of degenerative eye diseases.

A common pathogenetic mechanism for degenerative eye diseases is the augmentation of oxidative stress in several eye structures with subsequent tissular damage.

We have developed an inovative topical formulation with lutein (eye drops) which is non-invasive and easy to apply into the eyes.

Lutein was entrapped in a nanostructured carrier and placed in a thermosensitive, mucoadhesive gel. The novel formulation facilitated and improved the access of lutein to inner eye structures, leading to a superior ocular bioavailability, but also improved the chemical stability of the active substance.

  • Discuss
    Your Legal Issue

    Grursus mal suada faci lisis of Lorem the as ipsum dolarorit consectetur.

  • Introduction to
    Recommended Lawyers

    Grursus mal suada faci lisis of Lorem the as ipsum dolarorit consectetur.

  • Choose
    Your Advisor

    Grursus mal suada faci lisis of Lorem the as ipsum dolarorit consectetur.

  • Book
    an Appointment

    Grursus mal suada faci lisis of Lorem the as ipsum dolarorit consectetur.

Have You Any Questions?
We are always here to help you

1825

Completed Works

69

Winning Awards

532

Satisfied Clients

27

Team Members

1825

Completed Works

532

Satisfied Clients

69

Winning Awards

27

Team Members

Testimonial

What Our
Clients Say That

Team Members

People behind this project

Partners

Traffic Tickets

Criminal Lawyer

Insurance Defense

Banking & Finance

One More Case Won

Health Law

Criminal Justice

Business Company
Contact Us

Let's get in touch

Leave us your message below and we will get back as soon as possible to you. 

    Our Latest News